Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Human Hypertension

• Publication date

  2004-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.jhh.1001748PMID 15229622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

  2015cited by this paper
• The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study

  2004cited by this paper
• Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.

  2004cited by this paper
• The Effect of Short-Term Treatment with Simvastatin on Renal Function in Patients with Peripheral Arterial Disease

  2004cited by this paper
• Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• Coronary imaging: angiography shows the stenosis, but IVUS, CT, and MRI show the plaque.

  2003cited by this paper
• The EUROPA trial

  2003cited by this paper
• The effects of lipid-regulating therapy on haemostatic parameters.

  2003cited by this paper
• Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients

  2003cited by this paper
• The effects of antihypertensive therapy on haemostatic parameters.

  2003cited by this paper
• Early Benefit from Structured Care with Atorvastatin in Patients with Coronary Heart Disease and Diabetes Mellitus

  2003cited by this paper
• Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial.

  2003cited by this paper
• Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.

  2003cited by this paper
• Early vascular benefits of statin therapy

  2003cited by this paper
• Statins and Renal Function

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).

  2002cited by this paper
• Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention

  2002cited by this paper
• Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction.

  2002cited by this paper
• Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors.

  2002cited by this paper
• Comparison of Endothelial Pleiotropic Actions of Angiotensin Converting Enzyme Inhibitors and Statins

  2001cited by this paper
• Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.

  2001cited by this paper
• Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

  2001cited by this paper
• Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992

  2000cited by this paper
• Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined.

  2000cited by this paper
• Aortic stiffness as a risk factor for recurrent acute coronary events in patients with ischaemic heart disease.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)

  2000cited by this paper
• Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey.

  2000cited by this paper
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

  2000cited by this paper
• Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects.

  1999cited by this paper
• Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia.

  1999cited by this paper
• Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction.

  1999cited by this paper
• The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).

  1998cited by this paper
• Mechanism of protective effects of ACE inhibition on coronary artery disease.

  1998cited by this paper
• Depressed heart rate variability is associated with events in patients with stable coronary artery disease and preserved left ventricular function. REGRESS Study Group.

  1998cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population.

  1997cited by this paper
• Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study.

  1997cited by this paper
• Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.

  1996cited by this paper
• Presence of cardiovascular structural changes in essential hypertensive patients with coronary microvascular disease and effects of long-term treatment.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.

  1995cited by this paper
• A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.

  1994cited by this paper
• Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

  1992cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• Cardiovascular structural changes in hypertension: possible regression during long-term antihypertensive treatment.

  1991cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease.

  2024cites this paper
• Simvastatin and Captopril Combined Transdermal Delivery System for Controlling Blood Pressure and Fat: Design, Characterization, and In Vivo Pharmacokinetic Evaluation

  2024cites this paper
• Polypill use for the prevention of cardiovascular disease: a position paper.

  2023cites this paper
• Paying more attention to arterial hypertension, dyslipidaemia, women and the rural environment in our ongoing fight against cardiovascular diseases and their risk factors.

  2023cites this paper
• The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.

  2022cites this paper
• The Effects of a Perindopril-Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials

  2022cites this paper
• Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial

  2022cites this paper
• Potential of combination therapy in patients with hypertension and dyslipidemia

  2022cites this paper
• Hypertension and Hypercholesterolemia: Let's Make Therapy Easy and Efficient.

  2022cites this paper
• Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development

  2022cites this paper
• Chaotropic salts impact in HPLC approaches for simultaneous analysis of hydrophilic and lipophilic drugs.

  2021cites this paper
• Bespoke 3D-Printed Polydrug Implants Created via Microstructural Control of Oligomers.

  2021cites this paper
• Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis.

  2021cites this paper
• ROBUSTNESS EVALUATION OF HPLC DETERMINATION OF ATORVASTATIN AND LISINOPRIL ON COLUMN PUROSPHER C8 STAR IN PHARMACEUTICALS

  2021cites this paper
• Beneficial effect of ACE inhibitors on kidney function in polycythemia vera

  2021cites this paper
• Estudio farmacodinámico del policomprimido cardiovascular: ¿existe algún tipo de interacción entre los monocomponentes?

  2020cites this paper
• Monotherapy versus combination therapy of statin and renin–angiotensin system inhibitor in ST-segment elevation myocardial infarction

  2020cites this paper
• Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?

  2020cites this paper
• Predicting Drug-Drug Interactions Based on Integrated Similarity and Semi-Supervised Learning

  2020cites this paper
• DUSP1 Is a Potential Marker of Chronic Inflammation in Arabs with Cardiovascular Diseases

  2018cites this paper
• Comparison Therapies in the Treatment of Hypertension. The ASCOT and ACCOMPLISH Trial

  2018cites this paper
• In Patients with Cardiovascular Disease, Do Statins Alone, or in Combination with Other Medications Improve Mortality?

  2017cites this paper
• The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?

  2017cites this paper
• Practical solutions for hypertensive patients with dyslipidemia

  2017cites this paper
• Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease

  2017cites this paper
• Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.

  2017cites this paper
• Combining Potent Statin Therapy with Other Drugs to Optimize Simultaneous Cardiovascular and Metabolic Benefits while Minimizing Adverse Events

  2017cites this paper
• Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease: A Prospective Observational Study

  2016cites this paper
• The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease

  2016influential citation
• Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine

  2016cites this paper
• 3 Current Therapeutic Needs in Hypertensive Patients with Hypercholesterolemia or Stable Coronary Artery Disease ( CAD )

  2016cites this paper
• Comparative Effects of Statin Therapy versus Renin-Angiotensin System Blocking Therapy in Patients with Ischemic Heart Failure Who Underwent Percutaneous Coronary Intervention

  2016cites this paper
• Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?

  2015cites this paper
• Renin–angiotensin system inhibitor and statins combination therapeutics – what have we learnt?

  2015cites this paper
• The Mechanisms Responsible for Atherosclerosis Development in Arterial Hypertension and Hypercholesterolemia

  2015cites this paper
• Hypercholesterolemia and Hypertension: Two Sides of the Same Coin

  2015cites this paper
• The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.

  2015cites this paper
• Clinical prospects for dyslipidemia treatment in patients with arterial hypertension

  2015cites this paper
• Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.

  2014cites this paper
• Combination of statin plus renin angiotensin system inhibition for the prevention or the treatment of atherosclerotic cardiovascular disease.

  2014cites this paper
• Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis.

  2014cites this paper
• Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?

  2014cites this paper
• Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review

  2013cites this paper
• Evaluation of Adverse Effects of Lisinopril and Rosuvastatin on Hematological and Biochemical Analytes in Wistar Rats

  2013influential citation
• Treating Arterial Stiffness Associated with Features of Metabolic Syndrome Not Included in its Diagnostic Criteria: Cutting Off the Heads of Lernaean Hydra, Keeper of the Underworld

  2013cites this paper
• Antihypertensive Effects of Statins: A Meta‐Analysis of Prospective Controlled Studies

  2013cites this paper
• Improved long-term survival in patients on combination therapies following an incident acute myocardial infarction: a longitudinal population-based study

  2013cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• Lipid lowering agents and the endothelium: an update after 4 years.

  2012cites this paper
• Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?

  2011cites this paper
• Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study

  2011cites this paper
• Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.

  2011cites this paper
• Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?

  2011cites this paper
• Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach

  2011cites this paper
• Statin discontinuation: counterbalancing the benefits with the potential risks

  2011cites this paper
• Current role of statins in the treatment of essential hypertension

  2010cites this paper
• Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention.

  2009cites this paper
• Cumulative Gains in Stroke Prevention With Optimal Control of Each Additional Risk Factor

  2009cites this paper
• Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study

  2009cites this paper
• Role and significance of statins in the treatment of hypertensive patients

  2009cites this paper
• Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?

  2009cites this paper
• Do we need to consider inflammatory markers when we treat atherosclerotic disease?

  2008cites this paper
• Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.

  2007cites this paper
• Analysis of antihypertensive effects of statins

  2007cites this paper
• Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice

  2007cites this paper
• Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?

  2007cites this paper
• The Importance of Managing Hypertension and Dyslipidemia to Decrease Cardiovascular Disease

  2007cites this paper
• Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1–7) is associated with suppression of superoxide release

  2007cites this paper
• Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients

  2007cites this paper
• Lipid-Altering Therapies and the Progression of Atherosclerotic Disease

  2007cites this paper
• Emerging indications for statins: a pluripotent family of agents with several potential applications.

  2007cites this paper
• [About dyslipidemic states characteristic for various forms of ischemic heart disease and cerebrovascular damages].

  2007cites this paper
• Is the metabolic syndrome a real clinical entity and should it receive drug treatment?

  2006cites this paper
• ACE-Inhibition for Secondary Prevention of Cardiovascular Events—Should We Change Our Recommendation After PEACE?

  2006cites this paper
• Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence

  2006cites this paper
• Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2) guidelines

  2006cites this paper
• Chicken's valve in a human heart.

  2006cites this paper
• Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits

  2006cites this paper
• Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?

  2006cites this paper
• Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?

  2006cites this paper
• Statins: another class of antihypertensive agents?

  2006cites this paper
• Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

  2006cites this paper
• Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study

  2005cites this paper
• Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease

  2005cites this paper
• Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence?

  2005cites this paper
• Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Meta

  2005cites this paper
• Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

  2004cites this paper
• Lipid-lowering therapies in development

  2004cites this paper